PROVIDENCE – A researcher of mosquito-borne illness at the University of Rhode Island has received an $11 million grant from the National Institutes of Health to continue his studies, his second largest grant and one of the largest ever for the university, URI announced Friday.
Professor Alan Rothman, who came to URI in 2011 from the University of Massachusetts Medical School in Worcester, Mass., will use the new, $11.4 million grant from NIH to continue his studies of dengue fever, a sometimes deadly disease carried by mosquitoes that infects about 100 million people a year in the tropics and sub-tropics.
The award was made in July, the university said.
Dr. Rothman won a comparable $11 million grant from NIH in 2008 while at UMass, according to URI.
His work includes lab research at The Institute for Immunology and Informatics, field studies in Thailand and the Philippines, and collaborations with scientists at Brown University, Rhode Island Hospital, Walter Reed Army Institute of Research, and other institutions.
Dengue fever has flu-like symptoms and is not usually fatal, but can be debilitating. The disease is known in the U.S. primarily from travelers to the tropics who are bitten by disease-carrying mosquitoes.
Dr. Rothman will formally announce the award at a briefing Monday, Aug. 5 at 10 a.m. on the third floor of the institute at the URI Providence campus, 80 Washington St., Providence.
In 2011, Dr. Rothman described himself as an immunologist who facilitates vaccine development, according to the release.
Join PBN and two panels of successful female executives, business owners and entrepreneurs as we delve into what women should do to advance their careers, and become leaders in the corporate world and their own enterprises.
PBN's annual Book of Lists has been an essential resource for the local business community for almost 30 years. The Book of Lists features a wealth of company rankings from a variety of fields and industries, including banking, health care, real estate, law, hospitality, education, not-for-profits, technology and many more.